DRW Securities’s Intellia Therapeutics NTLA Stock Holding History

DRW Securities’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,268	Closed	-$153K	–	1527
2025 Q2	$153K	Buy	+16,268	New	+$134K	﹤0.01%	994

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CGH

Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DRW Securities's NTLA Position: Q3 2025 in Review

DRW Securities sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 16,268 shares — an estimated $153K sold.

DRW Securities first reported a position in NTLA in Q2 2025 and held it in 1 quarter. The position peaked at $153K in Q2 2025. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

DRW Securities reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
DRW Securities sold 16,268 Intellia Therapeutics shares in Q3 2025, an estimated $153K.
DRW Securities first reported a position in Intellia Therapeutics in Q2 2025 and held it in 1 quarter.
DRW Securities's Intellia Therapeutics position peaked at $153K in Q2 2025.
282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on DRW Securities's 13F filing for Q3 2025, filed 14 Nov 2025.